Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.22.2.2
Segment Information (Tables)
3 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of financial information by reportable segment

The following is financial information relating to the Company's reportable segments (in thousands):

Quarter Ended

September 30, 

    

2022

    

2021

Net sales:

 

  

Protein Sciences

$

199,949

  

$

197,186

Diagnostics and Genomics

 

69,904

 

60,985

Intersegment

 

(198)

 

(452)

Consolidated net sales

$

269,655

  

$

257,719

Operating income:

 

  

 

  

Protein Sciences

$

85,942

  

$

90,100

Diagnostics and Genomics

 

8,638

 

7,463

Segment operating income

$

94,580

$

97,563

Costs recognized on sale of acquired inventory

 

(300)

 

(1,512)

Amortization of acquisition related intangible assets

 

(19,283)

 

(18,389)

Impact of partially-owned consolidated subsidiaries(1)

 

647

 

(1,562)

Acquisition related expenses

 

(297)

 

2,377

Stock based compensation, inclusive of employer taxes

 

(15,458)

 

(13,860)

Restructuring costs

 

(2,170)

 

(1,185)

Corporate general, selling, and administrative expenses

 

(1,402)

 

(210)

Consolidated operating income

$

56,317

  

$

63,222

(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party